COLCIBRA

This brand name is authorized in Nigeria. It is also authorized in Ecuador.

Active ingredients

The drug COLCIBRA contains one active pharmaceutical ingredient (API):

1	Celecoxib UNII JCX84Q7J1L - CELECOXIB
	Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.
	Read more about Celecoxib

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-1692	Capsule	Colcibra 100 mg Capsules CAP 100 mg 3 x 10's	Capsule	07/05/2021
C4-1693	Capsule	Colcibra 200 mg Capsules CAP 200 mg 3 x 10's	Capsule	07/05/2021

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M01AH01	Celecoxib	M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AH Coxibs
Discover more medicines within M01AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	24.954-02-03
NG	Registered Drug Product Database	C4-1692, C4-1693